#proprietarystemcelltechnology

[thxnews]

Cell BioEngines, Miltenyi Forge HSCT Manufacturing Deal

Innovating Blood Cancer Treatment

Cell BioEngines, Inc., a trailblazer in stem cell and immune cell therapies for blood and solid cancers, has announced a strategic partnership with Miltenyi Bioindustry. This collaboration aims to develop and manufacture an expanded hematopoietic stem cell transplantation (HSCT) product, marking a significant advancement in hematology-oncology clinical applications.   Revolutionizing Bone Marrow Transplantation Cell BioEngines is set to transform blood cancer treatment with its proprietary stem cell expansion technology. This 'off-the-shelf' curative approach for bone marrow transplant patients uses a patented small molecule to enhance the number of hematopoietic stem cells from umbilical cord blood, addressing the critical issue of donor availability for allogenic HSCT.  

Miltenyi's Expertise in GMP Manufacturing

Streamlining Clinical Trial Preparations Under the agreement, Miltenyi will initiate development leading to Good Manufacturing Practices (GMP) manufacturing of Phase 1 clinical trial batches for Cell BioEngines' CBE-101 clinical program. Dr. Ajay Vishwakarma, CEO of Cell BioEngines, emphasized the benefits of this partnership, allowing the company to focus on developing safer, more effective stem cell cancer treatments.   Integrating Cutting-Edge Platforms for HSC Therapies Miltenyi brings to the table its proprietary platforms for cell processing and analysis, crucial for HSC therapies. Leonard Pulig, President of Miltenyi Biotec, highlights the CliniMACS Prodigy® platform's role in optimizing HSC isolation and expansion. This collaboration also involves integrating the platform with bioreactors for large-scale manufacturing, demonstrating Miltenyi's prowess in cell therapy process development and product scale-up.  

Financial Terms and Future Prospects

Although the partners have not disclosed the financial details of the agreement, the Cell BioEngines and Miltenyi collaboration is set to achieve significant advancements in the field of hematopoietic cell therapy.   About Cell BioEngines Cell BioEngines, Inc. actively pursues the revolution of cancer treatment, developing allogenic cell therapies conceptualized as 'drugs,' aiming ambitiously to turn all cancers into curable diseases. Furthermore, their pioneering Stem-SPACE™ platform technology plays a crucial role in this endeavor. Importantly, it facilitates the production of clinical-grade cells on a large scale. Additionally, this innovative approach enables Cell BioEngines to explore a diverse array of cell and gene therapy product candidates. Each of these candidates holds significant promise, not just in clinical effectiveness but also in commercial viability. Moreover, the company's focus extends beyond mere treatment to potentially curing various forms of cancer. This goal is rooted in their cutting-edge research and development efforts. Furthermore, the versatility of the Stem-SPACE™ platform positions Cell BioEngines at the forefront of the biotech industry. Significantly, it allows for rapid adaptation and response to emerging therapeutic needs and challenges in oncology. Consequently, this positions Cell BioEngines as a key player in the future of cancer treatment, potentially transforming the landscape of medical care for cancer patients worldwide.   About Miltenyi Biotec Miltenyi Biotec, renowned as a global leader in biomedical research and cellular therapy advancement, consistently supports every stage of cell and gene therapy product development. Additionally, the company's comprehensive solutions have established industry benchmarks in manufacturing and analyzing complex cellular products. Moreover, Miltenyi's specialized division, Miltenyi Bioindustry, capitalizes on its expertise by developing and manufacturing lentiviral vectors and cell and gene therapy products. Importantly, this division employs the CliniMACS Prodigy® platform, effectively scaling from pre-clinical stages to commercial production. This strategic utilization of resources and technology underlines Miltenyi's commitment to advancing the field of cellular therapy.   Sources: THX News & Cell BioEngines, Inc. Read the full article